Assessing Prediction Performance of Neoadjuvant Chemotherapy Response in Bladder Cancer

Preprint OPEN
Cremer, Chris;
(2016)
  • Related identifiers: doi: 10.1101/075705
  • Subject: bepress|Life Sciences|Biology | bepress|Life Sciences|Bioinformatics

Neoadjuvant chemotherapy is a treatment routinely prescribed to patients diagnosed with muscle-invasive bladder cancer. Unfortunately, not all patients are responsive to this treatment and would greatly benefit from an accurate prediction of their expected response to c... View more
  • References (6)

    66, pp. 4-34, 2005.

    J. S. Chang, P. N. Lara, and C. X. Pan, “ Progress in personalizing chemotherapy for bladder cancer,” Adv. Urol., vol. 2012, 2012.

    Wood, D. Raghavan, and E. D. Crawford, “ Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.,” N. Engl. J. Med., vol. 349, pp.

    G. Griffiths, “ International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: Long-term results of the BA06 30894 trial,” J. Clin. Oncol., vol. 29, no. 16, pp. 2171-2177, 2011.

    Quiroga, S. Benlloch, L. Ibarz, and R. Rosell, “ BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer,” Ann. Oncol., vol. 22, no. July 2010, pp. 139-144, 2011.

    B. Kiss, M. D, V. Skuginna, M. D, A. Fleischmann, M. D, R. H. Bell, C. Collins, D. Ph, G. N. Thalmann, M. D, R. Seiler, and M. D, “ BclFig 5: A) Neural Network Training (dashed blue) and Test Error (solid green) over 300 epochs on microarray data. B) Same network applied to random data for comparison.

  • Metrics
    No metrics available
Share - Bookmark

  • Download from
    bioRxiv via bioRxiv (Preprint, 2016)
  • Cite this publication